These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 19782150)

  • 1. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.
    van Rijt SH; Sadler PJ
    Drug Discov Today; 2009 Dec; 14(23-24):1089-97. PubMed ID: 19782150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.
    Lazarević T; Rilak A; Bugarčić ŽD
    Eur J Med Chem; 2017 Dec; 142():8-31. PubMed ID: 28442170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer metallodrugs: where is the next cisplatin?
    Hanif M; Hartinger CG
    Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Cancer Cell-Selective and Low-Toxic Bifunctional Heterodinuclear Pt(IV)-Ru(II) Anticancer Prodrug.
    Ma L; Lin X; Li C; Xu Z; Chan CY; Tse MK; Shi P; Zhu G
    Inorg Chem; 2018 Mar; 57(5):2917-2924. PubMed ID: 29436828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer prodrugs: an overview of major strategies and recent developments.
    Arpicco S; Dosio F; Stella B; Cattel L
    Curr Top Med Chem; 2011; 11(18):2346-81. PubMed ID: 21671864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What do we know about the reduction of Pt(IV) pro-drugs?
    Wexselblatt E; Gibson D
    J Inorg Biochem; 2012 Dec; 117():220-9. PubMed ID: 22877926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel metals and metal complexes as platforms for cancer therapy.
    Frezza M; Hindo S; Chen D; Davenport A; Schmitt S; Tomco D; Dou QP
    Curr Pharm Des; 2010 Jun; 16(16):1813-25. PubMed ID: 20337575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition Metal-Based Prodrugs for Anticancer Drug Delivery.
    Phillips AMF; Pombeiro AJL
    Curr Med Chem; 2019; 26(41):7476-7519. PubMed ID: 30501593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metal-based photosensitizers for photodynamic therapy: the future of multimodal oncology?
    McFarland SA; Mandel A; Dumoulin-White R; Gasser G
    Curr Opin Chem Biol; 2020 Jun; 56():23-27. PubMed ID: 31759225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting drug delivery system for platinum(Ⅳ)-Based antitumor complexes.
    Zhong Y; Jia C; Zhang X; Liao X; Yang B; Cong Y; Pu S; Gao C
    Eur J Med Chem; 2020 May; 194():112229. PubMed ID: 32222677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy.
    Hecel A; Kolkowska P; Krzywoszynska K; Szebesczyk A; Rowinska-Zyrek M; Kozlowski H
    Curr Med Chem; 2019; 26(4):624-647. PubMed ID: 28933286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Chemotherapeutic Agents - The Contribution of Scorpionates.
    Andrade MA; Martins LMDRS
    Curr Med Chem; 2019; 26(41):7452-7475. PubMed ID: 30215328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum(IV) anticancer agents; are we en route to the holy grail or to a dead end?
    Gibson D
    J Inorg Biochem; 2021 Apr; 217():111353. PubMed ID: 33477089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches.
    Galanski MS; Jakupec MA; Keppler BK
    Curr Med Chem; 2005; 12(18):2075-94. PubMed ID: 16101495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of hypoxic and acidic tumor environments with a cobalt(III) chaperone complex.
    Yamamoto N; Renfrew AK; Kim BJ; Bryce NS; Hambley TW
    J Med Chem; 2012 Dec; 55(24):11013-21. PubMed ID: 23199008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.
    Gabano E; Ravera M; Zanellato I; Tinello S; Gallina A; Rangone B; Gandin V; Marzano C; Bottone MG; Osella D
    Dalton Trans; 2017 Oct; 46(41):14174-14185. PubMed ID: 28984330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP).
    Jagathesan K; Roy S
    ChemMedChem; 2024 Jul; 19(14):e202400127. PubMed ID: 38634306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.